Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
August 07 2019 - 8:24AM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-214350
PROSPECTUS SUPPLEMENT
NO. 2 DATED AUGUST 7, 2019
TO
PROSPECTUS DATED
NOVEMBER 25, 2016
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 9,415,546 Shares of Common Stock
This Prospectus Supplement No. 2 supplements
the prospectus of Arch Therapeutics, Inc. (“the “
Company
”, “
we
”, “
us
”,
or “
our
”) dated November 25, 2016
(as supplemented to date, the “
Prospectus
”)
with the following additions and changes:
|
A.
|
Amend the Selling Securityholder information set forth in the Prospectus.
|
This Prospectus Supplement No. 2 should be read in conjunction
with the Prospectus, which is required to be delivered with this Prospectus Supplement.
This
prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency
between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.
This
prospectus
supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any
amendments or supplements to it.
Investing in our common stock involves a high degree of risk.
Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are
described in the Prospectus, as amended or supplemented.
You should rely only on the information contained in the
Prospectus, as supplemented or amended by this Prospectus Supplement No. 2 and any other prospectus supplement or amendment thereto.
We have not authorized anyone to provide you with different information.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement No.
2 is August 7, 2019
INDEX TO FILINGS
|
Annex
|
Amendment to Selling Securityholder Information
|
A
|
ANNEX A
AMENDMENT TO SELLING SECURITYHOLDER INFORMATION
This Prospectus Supplement No. 2 is being filed in connection
with certain changes to the selling securityholder information as set forth in the Prospectus dated November 25, 2016
(as
supplemented to date, the “
Prospectus
”)
resulting from the transfer by by Tungsten III, LLC (“
Tungsten
”),
an entity controlled by Michael A. Parker, of its Series D Warrants to Ana B. Parker, Mr. Parker’s wife. Consequently, the
selling securityholders table (the “
Selling Securityholders Table
”) appearing under the heading “SELLING
SECURITYHOLDERS” in the Prospectus is hereby amended and supplemented by (i) deleting the information for the Tungsten in
the Selling Securityholders Table; (ii) adding the following information for Ms. Parker to the Selling Securityholders Table; and
(iii) updating footnotes (1) through (5):
Column 1
|
Column 2
|
Column 3
|
Column 4
|
Column 5
|
Column 6
|
Name of Selling Securityholder
|
Number of Shares of Common Stock Issued and Issuable (1)
|
Number of Shares of Common Stock Beneficially Owned Prior to this Offering (2)
|
Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus (3)
|
Number of Shares of Common Stock Beneficially Owned After This Offering (4)
|
Percentage of Shares of Common Stock Beneficially Owned After This Offering (5)
|
Ana B Parker (19)
|
12,348,932
|
4,434,829
|
1,583,334
|
4,434,829
|
3.35%
|
|
(1)
|
Reflects the total number of shares of Common Stock held or issuable to each selling securityholder including, to the extent
applicable, (a) all remaining securities issued in the 2016 Private Placement Financing, in each case without regard to ownership
limitations on the exercise of certain of the Series E Warrants as described in footnote (2) below; (b) all remaining securities
issued in the 2015 Private Placement Financing (and together with the 2016 Private Placement Financing, the “
Private Placement
Financings
”), none of which are being registered in the 2016 S-3 Registration Statement of which this prospectus forms
a part and in each case without regard to the ownership limitations on the exercise of certain of the Series D Warrants as described
in footnote (2) below; (c) all remaining securities issued in connection with the registered direct offering that closed on July
2, 2018 (the “
2018 Financing
”), none of which are being registered in the 2016 S-3 Registration Statement of
which this prospectus forms a part and in each case without regard to the ownership limitations on the exercise of the Series G
Warrants as described in footnote (2) below; (d) all remaining securities issued in connection with the registered direct offering
that closed on May 14, 2019 (the “
2019 Financing
”, and together with the Private Placement Financings and 2018
Financing, the “
Equity Financings
”), none of which are being registered in the 2016 S-3 Registration Statement
of which this prospectus forms a part and in each case without regard to the ownership limitations on the exercise of the Series
H Warrants as described in footnote (2) below; and (e) all other securities issued in transactions unrelated to the Equity Financings,
if any, none of which are being registered in the 2016 S-3 Registration Statement of which this prospectus forms a part and in
each case without regard to any ownership limitations upon the exercise or conversion of such securities.
|
|
(2)
|
Certain of the Series E and Series D Warrants issued in the 2016 Private Placement Financing and 2015 Private Placement Financing,
respectively and all the Series G Warrants and Series H Warrants issued in the 2018 Financing and 2019 Financing, respectively,
contain ownership limitations to prevent the exercise of such warrants in certain circumstances. In particular, certain of the
Series E Warrants provide that they shall not be exercisable in the event and to the extent that the exercise thereof would result
in the holder of the Series E Warrant, together with its affiliates and any other persons whose beneficial ownership of Common
Stock would be aggregated with the holder’s, would be deemed to beneficially own more than 4.99% of the Common Stock;
provided,
however
, the (i) holder, upon notice to us, may increase or decrease this ownership limitation so long as the maximum ownership
limitation does not exceed 9.99% of the Company’s Common Stock; and (ii) any increase in the ownership limitation will not
become effective until the 61st day after delivery of such notice. Similarly, certain of the Series D Warrants provide that a selling
securityholder may not exercise such warrants to the extent (but only to the extent) that the exercise thereof would result in
the selling securityholder or any of its affiliates beneficially owning more than 4.9% of our Common Stock after giving effect
to such exercise;
provided, however
, that in the case of any Series D Warrant with an ownership limitation, the holder
may waive such ownership limitation, in which case such waiver will become effective sixty-one (61) days after the holder’s
delivery of such wavier notice. Finally, the Series G Warrants and Series H Warrants provide that they may not be exercised if
the holder, together with its affiliates and any other persons whose beneficial ownership of the Common Stock would be aggregated
with the holder’s, would be deemed to beneficially own more than 4.99% of the Common Stock;
provided, however
, the
(i) holder, upon notice to us, may increase this ownership limitation so long as the maximum ownership limitation does not exceed
9.99% of the Company’s Common Stock; and (ii) any increase in the ownership limitation will not become effective until the
61st day after delivery of such notice.
|
As a result, the number of shares
of Common Stock reflected in this column as beneficially owned by each selling securityholder includes, to the extent applicable,
(a) the shares of Common Stock that were issued in the 2016 Private Placement Financing held by such selling securityholder and/or
issuable upon exercise of the Series E Warrants held by such selling securityholder which, in the case of any Series E Warrant
with an ownership limitation that has not been previously waived, is limited to the number of shares of Common Stock that such
selling securityholder has the right to acquire without it (along with any of its affiliates or any other persons whose beneficial
ownership of Common Stock would be aggregated with the selling securityholder) beneficially owning more than 4.99% (or up to 9.99%
at the securityholders’ discretion) of our currently outstanding Common Stock; (b) the shares of Common Stock that were issued
in the Closings conducted for the 2015 Private Placement Financing held by such selling securityholder and/or issuable upon exercise
of the Series D Warrants held by such selling securityholder which, in the case of any Series D Warrant with an ownership limitation
that has not been previously waived, is limited to the number of shares of Common Stock that such selling securityholder has the
right to acquire without it or any of its affiliates beneficially owning more than 4.9% of our currently outstanding Common Stock;
(c) the shares of Common Stock that were issued in the 2018 Financing held by such selling securityholder and/or issuable upon
exercise of the Series G Warrants held by such selling securityholder which is limited to the number of shares of Common Stock
that such selling securityholder has the right to acquire without it (along with any of its affiliates or any other persons whose
beneficial ownership of Common Stock would be aggregated with the selling securityholder) beneficially owning more than 4.99% (or
up to 9.99% at the securityholders’ discretion) of our currently outstanding Common Stock; (d) the shares of Common Stock
that were issued in the 2019 Financing held by such selling securityholder and/or issuable upon exercise of the Series H Warrants
held by such selling securityholder which is limited to the number of shares of Common Stock that such selling securityholder has
the right to acquire without it (along with any of its affiliates or any other persons whose beneficial ownership of Common Stock
would be aggregated with the selling securityholder) beneficially owning more than 4.99% (or up to 9.99% at the securityholders’
discretion) of our currently outstanding Common Stock; and (e) shares of our Common Stock beneficially owned by such selling securityholder
that were acquired in transactions unrelated to the Equity Financings.
|
(3)
|
For each selling securityholder, the totals reported in this column reflect the total number of shares of Common Stock registered
for resale under the 2016 S-3 Registration Statement of which this prospectus forms a part including (a) the shares of Common Stock
held by such selling securityholder that were issued in connection with the Closings conducted for the 2016 Private Placement Financing
and/or, to the extent applicable, acquired upon the exercise of the Series E Warrants; and (b) shares of Common Stock issuable
upon exercise of the Series E Warrants held by such selling securityholder, in each case without taking into account the ownership
limitations set forth in the Series E Warrants as described in footnote (2).
|
|
(4)
|
For each selling securityholder and to the extent applicable, the totals reported in this column reflect the ownership limitations
set forth in the Series D, E, G and H Warrants described in footnote (2), and assume that (a) all of the shares of Common Stock
to be registered by the 2016 S-3 Registration Statement of which this prospectus forms a part, including the shares of Common Stock
issuable upon exercise of the Series D Warrants held by such selling securityholder (in each case without taking into account the
ownership limitations set forth in certain of the Series D Warrants as described in footnote (2)), are sold in this offering; and
(b) the selling securityholders do not (i) sell any of the securities that have been issued to them in transactions unrelated to
the 2015 Private Placement Financing (including, but not limited to, the 2016 Private Placement Financing and the 2014 Private
Placement Financing) and included in Column 2; and (ii) acquire additional shares of our Common Stock after November 23, 2016 and
prior to completion of this offering.
|
|
(5)
|
Percentage ownership for each selling securityholder is determined in accordance with Section 13(d) of the Exchange Act and
is based on 173,577,233 outstanding shares of our Common Stock as of August 7, 2019, and assumes that all shares underlying such
selling securityholder’s Series D Warrants that are being offered by such selling securityholder by this prospectus have
been issued and are outstanding.
|
|
(19)
|
Ms. Parker may be deemed to have beneficial ownership of 4,434,829 shares of Common Stock, which consists of (i) 1,210,495
shares of Common Stock that were originally issued to Ms. Parker’s IRA in connection with the 2016 Private Placement Financing
and subsequently transferred by her IRA to her in her personal capacity, none of which are being registered in the 2016 S-3 Registration
Statement of which this prospectus forms a part; (ii) 788,800 shares of Common Stock that were issued to Ms. Parker in connection
with the registered direct offering that closed on July 2, 2018 (the “
2018 Financing
”), none of which are being
registered in the 2016 S-3 Registration Statement of which this prospectus forms a part; (iii) 1,230,769 shares of Common Stock
that were issued to Ms. Parker in connection with the registered direct offering that closed on May 14, 2019 (the “
2019
Financing
”, and together with the Private Placement Financings and 2018 Financing, the “
Equity Financings
”),
none of which are being registered in the 2016 S-3 Registration Statement of which this prospectus forms a part; and (iv) 1,204,765
shares of Common Stock acquired by Ms. Parker in transactions unrelated to the Equity Financings, none of which are being registered
in the 2016 S-3 Registration Statement of which this prospectus forms a part. The shares of Common Stock being registered in the
2016 S-3 Registration Statement of which this prospectus forms a part consist of 1,583,334 shares of Common Stock issuable upon
exercise of Series E that were originally issued to Ms. Parker’s IRA in connection with the 2016 Private Placement Financing,
subsequently assigned to Tungsten III, LLC (“
Tungsten
”), an entity controlled by Michael A. Parker, Ms. Parker’s
spouse, and then assigned by Tungsten to Ms. Parker, effective as of May 30, 2019. The information presented for Ms. Parker in
Column 3 of this table excludes (a) 4,500,000 shares of Common Stock issuable upon exercise of Series D Warrants that were originally
issued to Mr. Parker, an investor in the 2015 Private Placement Financing, subsequently assigned by Mr. Parker to Tungsten, and
then assigned by Tungsten to Ms. Parker, effective as of May 30, 2019, none of which are being registered in the 2016 S-3 Registration
Statement of which this prospectus forms a part; (b) 600,000 shares of Common Stock issuable upon exercise of Series G Warrants
that issued to Ms. Parker in connection with the 2018 Financing, none of which are being registered in the 2016 S-3 Registration
Statement of which this prospectus forms a part; (c) 1,230,769 shares of Common Stock issuable upon exercise of Series H Warrants
that issued to Ms. Parker in connection with the 2019 Financing, none of which are being registered in the 2016 S-3 Registration
Statement of which this prospectus forms a part; (d) 5,000,000 shares of Common Stock that were originally issued to Mr. Parker
in connection with the 2015 Private Placement Financing and subsequently assigned by Mr. Parker to Tungsten, none of which are
being registered in the 2016 S-3 Registration Statement of which this prospectus forms a part; and (e) 1,380,891 shares of Common
Stock acquired by Mr. Parker in transactions unrelated to the Equity Financings, none of which are being registered
in the 2016 S-3 Registration Statement of which this prospectus forms a part.
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Apr 2023 to Apr 2024